Precision Medicine Transformed Oncology —It’s Time to Do the Same for Sepsis
It’s time we reignite treatment development for sepsis and other immune-mediated conditions that strike when patients are most vulnerable.
Bobby Reddy, Jr. and Dr. Nathan Shapiro
Bobby Reddy, Jr., Ph.D. is Co-Founder and CEO of Prenosis, a biology-driven technology company that develops and implements integrated diagnostic-therapeutic products in acute care to improve patient outcomes. Since founding Prenosis in 2016, Bobby has led the company to achieve significant milestones, including the groundbreaking FDA marketing authorization of Sepsis ImmunoScore® in April 2024, the first-ever FDA-authorized AI diagnostic tool for sepsis, recognized as one of TIME's Best Inventions of 2024.
Previously, Bobby served as Research Scientist at the University of Illinois at Urbana-Champaign, developing electrical point-of-care biosensors and managing strategic partnerships with Taiwan Semiconductor Manufacturing Company, Abbott Diagnostics, and Intel. Bobby holds a Ph.D. in Electrical Engineering from UIUC, an M.S. and B.S. in Electrical Engineering and a B.S. in Computer Engineering from UC Irvine. Named to Crain's Chicago Business 40 Under 40, his mission is “to see people differently – to tailor healthcare to each individual's biology.”
Dr. Nathan I. Shapiro is a Professor of Emergency Medicine at Harvard Medical School and attending physician in the Department of Emergency Medicine at Beth Israel Deaconess Medical Center. Dr. Shapiro is the Vice Chairman of Research for the Emergency Department. He received his medical degree from Temple University School of Medicine, completed an internship in transitional medicine at Cook County Hospital, followed by a residency in Emergency Medicine at the Harvard Affiliated Emergency Medicine.
Dr. Shapiro has an MPH in clinical effectiveness from the Harvard School of Public Health. He has over 200 original publications, including in JAMA, New England Journal of Medicine, and PLoS One. He lectures internationally on the approach to diagnosis and treatment of sepsis in the emergency department and has received multiple grants. In his research portfolio, he serves as a principal investigator and liaison with the FDA for companies seeking new indications for biomarkers and devices.